Cited 0 time in
SUVmax of F-18-FDG PET/CT in the differential diagnosis of benign and malignant thyroid nodules according to tumor volume
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kim, Tae Heon | - |
| dc.contributor.author | Ji, Yong Bae | - |
| dc.contributor.author | Song, Chang Myeon | - |
| dc.contributor.author | Kim, Ji Young | - |
| dc.contributor.author | Choi, Yun Young | - |
| dc.contributor.author | Park, Jeong Seon | - |
| dc.contributor.author | Tae, Kyung | - |
| dc.date.accessioned | 2022-07-15T22:08:52Z | - |
| dc.date.available | 2022-07-15T22:08:52Z | - |
| dc.date.issued | 2015-07 | - |
| dc.identifier.issn | 1477-7819 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/156898 | - |
| dc.description.abstract | Background: The aim of this study was to investigate whether the maximum standardized uptake value (SUVmax) measured on fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18-FDG PET/CT) could be used as the primary means of differential diagnosis of thyroid nodules when tumor volume is assessed. Methods: We studied 192 patients who underwent preoperative F-18-FDG PET/CT followed by thyroidectomy. We evaluated the correlation between the volume of thyroid nodules, F-18-FDG uptake on visual analysis, and the mean SUVmax measured on F-18-FDG PET/CT. Results: When stratified by tumor volume, the mean SUVmax was higher in malignant than in benign nodules in nodules >= 1 cm(3) (p < 0.001). However, it did not differ between benign and malignant nodules smaller than 1 cm(3). At a cut-off value of SUVmax of 6, the respective sensitivities of F-18-FDG PET/CT, ultrasonography, and fine needle aspiration cytology were 60.8, 96.4, and 99.1 %, and the respective specificities were 95.9, 98.2, and 96.8 %. Conclusions: F-18-FDG PET/CT is limited as a primary modality in the differential diagnosis of benign and malignant thyroid nodules because of its low sensitivity. | - |
| dc.format.extent | 6 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | BioMed Central | - |
| dc.title | SUVmax of F-18-FDG PET/CT in the differential diagnosis of benign and malignant thyroid nodules according to tumor volume | - |
| dc.type | Article | - |
| dc.publisher.location | 영국 | - |
| dc.identifier.doi | 10.1186/s12957-015-0635-1 | - |
| dc.identifier.scopusid | 2-s2.0-84988951070 | - |
| dc.identifier.wosid | 000357921300004 | - |
| dc.identifier.bibliographicCitation | World Journal of Surgical Oncology, v.13, pp 1 - 6 | - |
| dc.citation.title | World Journal of Surgical Oncology | - |
| dc.citation.volume | 13 | - |
| dc.citation.startPage | 1 | - |
| dc.citation.endPage | 6 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Oncology | - |
| dc.relation.journalResearchArea | Surgery | - |
| dc.relation.journalWebOfScienceCategory | Oncology | - |
| dc.relation.journalWebOfScienceCategory | Surgery | - |
| dc.subject.keywordPlus | POSITRON-EMISSION-TOMOGRAPHY | - |
| dc.subject.keywordPlus | FINE-NEEDLE-ASPIRATION | - |
| dc.subject.keywordPlus | PREOPERATIVE ASSESSMENT | - |
| dc.subject.keywordPlus | CANCER | - |
| dc.subject.keywordPlus | RISK | - |
| dc.subject.keywordAuthor | F-18-FDG PET/CT | - |
| dc.subject.keywordAuthor | Thyroid nodule | - |
| dc.subject.keywordAuthor | Thyroid cancer | - |
| dc.subject.keywordAuthor | Differential diagnosis | - |
| dc.subject.keywordAuthor | SUVmax | - |
| dc.identifier.url | https://wjso.biomedcentral.com/articles/10.1186/s12957-015-0635-1 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
